Sutro Biopharma reports Q4 loss, beats revenue estimates

From Nasdaq: 2025-03-13 19:30:02

Sutro Biopharma, Inc. (STRO) reported a quarterly loss of $0.89 per share, missing the Zacks Consensus Estimate of -$0.86. This is down from earnings of $0.42 per share a year ago, with an earnings surprise of -3.49%. The company’s revenues of $14 million surpassed expectations by 34.11%.

Despite a year-over-year revenue decrease, Sutro Biopharma has exceeded consensus revenue estimates in two of the last four quarters. The stock has declined 27.2% this year, compared to the S&P 500’s -4.8% decrease. Investors are watching for management’s earnings call commentary for future insights.

Aprea Therapeutics, Inc. (APRE) is expected to report a quarterly loss of $0.68 per share, a 26.1% increase from the previous year. Revenue is projected to be $0.45 million, up 4400% from the same quarter last year. The consensus EPS estimate for the quarter has not changed in the last 30 days.

Investors are advised to consider the company’s earnings outlook and industry trends when deciding on investing in Sutro Biopharma, Inc. (STRO). The Zacks Rank for STRO is currently #3 (Hold), indicating market performance in line with the overall industry. Monitoring earnings estimate revisions is crucial for stock performance.

For those considering investment opportunities, Zacks Investment Research offers a list of the 7 best stocks to buy for the next 30 days. The Zacks Rank system has historically outperformed the S&P 500, with an average annual gain of +24.08%. Access the free report for insights into potential investments.



Read more at Nasdaq: Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates